Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab (PD-1/CTLA-4 bispecific antibody) plus tofacitinib in immunotherapy-refractory advanced esophageal squamous cell carcinoma
ChiCTR2500115509Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab and tofacitinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: objective response rate at 12 weeks, safety and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500115509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115509.